Welcome to our dedicated page for Protara Therapeutics news (Ticker: TARA), a resource for investors and traders seeking the latest updates and insights on Protara Therapeutics stock.
Protara Therapeutics, Inc. (Nasdaq: TARA) is a clinical-stage biotechnology company developing therapies for cancer and rare diseases, and its news flow reflects progress across its investigational programs. Company announcements frequently highlight updates on TARA-002, an investigational cell-based therapy in development for non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs), as well as on IV Choline Chloride, an investigational phospholipid substrate replacement therapy for patients on long-term parenteral support.
Investors following TARA news can expect detailed coverage of clinical trial milestones, including interim data from the Phase 2 ADVANCED-2 trial in NMIBC and the Phase 2 STARBORN-1 trial in pediatric LMs. Recent press releases have discussed complete response rates, safety and tolerability findings, and regulatory feedback from the U.S. Food and Drug Administration (FDA) on potential registrational paths for TARA-002 in both BCG-unresponsive and BCG-naïve NMIBC populations.
News items also report on regulatory designations and programs, such as Breakthrough Therapy, Fast Track, and Rare Pediatric Disease designations for TARA-002 in LMs, and Fast Track and Orphan Drug Designations for IV Choline Chloride in patients on long-term parenteral nutrition. In addition, Protara’s releases describe participation of TARA-002 in the FDA’s Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) Program.
Another key theme in TARA news is capital markets activity, including underwritten public offerings of common stock under the company’s shelf registration statement on Form S-3, with proceeds directed toward the clinical development of TARA-002 and other programs. Corporate updates may reference conference presentations, such as appearances at healthcare conferences, and scheduled webcasts to review new clinical data.
By monitoring this news page, readers can follow Protara’s disclosed clinical data updates, regulatory interactions, financing events, and other material developments that the company reports through press releases and related communications.
Protara Therapeutics, Inc. (Nasdaq: TARA) has announced its participation in the H.C. Wainwright Global Investment Conference from May 23 to May 26, 2022. Their prerecorded presentation will be available on May 24, 2022, at 7:00 a.m. ET. Interested viewers can access it via the Events and Presentations section of Protara's website, where it will be archived for 90 days. Protara focuses on developing therapies for cancer and rare diseases, including TARA-002 for bladder cancer and IV Choline Chloride for intestinal failure-related liver disease.
Protara Therapeutics (Nasdaq: TARA) announced positive results from a retrospective analysis of OK-432, the basis for its investigational therapy TARA-002, targeting lymphatic malformations (LMs). Presented at the ISSVA World Congress 2022, the analysis involved 246 patients, showing approximately 69% clinical success in immediate treatment groups versus 7.5% in delayed groups. Serious adverse events were rare, with a favorable safety profile noted. These findings bolster the potential for TARA-002 to provide a much-needed FDA-approved treatment for LMs.
Protara Therapeutics (Nasdaq: TARA) announced dosing has begun in the Phase 1 ADVANCED-1 study of TARA-002 for non-muscle invasive bladder cancer (NMIBC). The company reported cash and investments of $119 million as of March 31, 2022, allowing funding through mid-2024. The Phase 2 trial for TARA-002 in lymphatic malformations is also planned following guidance from the FDA. Financially, R&D expenses decreased to $5.3 million from $7.0 million year-over-year, while the net loss narrowed to $10.8 million, or $0.96 per share.
Protara Therapeutics (Nasdaq: TARA) announced the dosing of the first patient in its Phase 1 clinical trial, ADVANCED-1, investigating TARA-002 for non-muscle invasive bladder cancer (NMIBC). This trial targets treatment-naïve and experienced patients with high-grade tumors. The primary goal is to evaluate TARA-002's safety and anti-tumor activity, setting the stage for a potential Phase 2 study. NMIBC accounts for 80% of bladder cancer cases, with a pressing need for effective treatment options.
Protara Therapeutics (TARA) has commenced a Phase 1 clinical trial of TARA-002 for non-muscle invasive bladder cancer (NMIBC), following FDA IND clearance in October 2021. The company reported a strong cash position of $130.7M as of December 31, 2021, expected to fund operations into mid-2024. Research and development expenses rose to $21.1M for 2021, up from $12.0M the previous year. Protara registered a net loss of $10.2M in Q4 2021, compared to $8.8M in Q4 2020, with total net losses of $47.3M for 2021.
Protara Therapeutics, Inc. (Nasdaq: TARA) announced participation in two virtual fireside chats at upcoming healthcare conferences. The Cowen 42nd Annual Health Care Conference is scheduled for March 9, 2022, at 9:10 am ET, followed by the Oppenheimer 32nd Annual Healthcare Conference on March 15, 2022, at 2:00 pm ET. Interested parties can access the live webcasts on Protara's website, where they will remain archived for 90 days. Protara focuses on innovative therapies for cancer and rare diseases, including its lead program TARA-002.
Protara Therapeutics, Inc. (Nasdaq: TARA) announced its participation in a virtual fireside chat at the Guggenheim Healthcare Talks 2022 Oncology Conference on February 9, 2022, at 4:00 PM ET. Interested parties can access the live webcast through the Events and Presentations section of the Company’s website, which will remain archived for 90 days post-event. Protara focuses on developing transformative therapies for cancer and rare diseases, including its lead program, TARA-002, aimed at treating non-muscle invasive bladder cancer and lymphatic malformations.
Protara Therapeutics (Nasdaq: TARA) has appointed Dr. Jathin Bandari as Chief Medical Officer. He previously served as the Vice President of Clinical Development and was Interim CMO. Dr. Bandari, a urologic oncologist with extensive experience, will lead the development of TARA-002, a therapy for non-muscle invasive bladder cancer. Under his leadership, Protara aims to advance its oncology portfolio and explore new applications for TARA-002. Dr. Bandari is a respected figure in oncology with a significant number of publications and contributions to the field.
Protara Therapeutics, Inc. (Nasdaq: TARA) will present at the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022. The presentation will be available on January 10 at 7:00 am ET through the Company's website. Protara focuses on developing therapies for cancer and rare diseases, featuring its lead program TARA-002 for non-muscle invasive bladder cancer and lymphatic malformations. Additionally, IV Choline Chloride targets intestinal failure-associated liver disease. The presentation will be archived for 90 days on their website.
Protara Therapeutics (TARA) announced significant advancements in its TARA-002 program, achieving FDA clearance for its IND application targeting non-muscle invasive bladder cancer (NMIBC). The company plans to initiate a Phase 1 clinical trial by year-end 2021. As of September 30, 2021, Protara reported strong cash reserves of $138.4 million, despite increasing R&D and administrative expenses leading to a net loss of $10.8 million for the quarter. The company also aims to engage the FDA for a trial design in lymphatic malformations.
FAQ
What is the current stock price of Protara Therapeutics (TARA)?
What is the market cap of Protara Therapeutics (TARA)?
